K. Rohr

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC.

F. Cappuzzo, W. Brugger, N. Triller, 2009, Journal of Clinical Oncology.

Association between different potential predictive markers from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC)

O. Spleiss, J. Moecks, M. Reck, 2007 .

9167 Outcomes with erlotinib in advanced NSCLC: examining the influence of increased EGFR gene copy number and EGFR mutations

F. Cappuzzo, T. Ciuleanu, L. Stelmakh, 2009 .